SuppreMol of Germany has raised €15.5 million in a series C financing round led by existing investors MIG and BioMedPartners.
SuppreMol will use the proceeds for the GMP production and further clinical studies of its lead candidate SM101, a recombinant human soluble Fc gamma receptor IIb for the treatment of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?